• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

MUVON Therapeutics

  • April 10, 2021
  • New Biotech Startups

MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation.

The technology behind MUVON was developed over the past decade at the University of Zurich and in recent years has been funded by the EU under the Horizon 2020 project known as MUS.I.C. The start-up MUVON was founded in 2020 to continue the development of the therapy and technology.

The technology enables the targeted isolation of muscle precursor cells (MPCs) from muscle tissue, the controlled expansion of these cells and the regeneration of muscle tissue through injection of the expanded cells.

The company’s initial area of focus is developing a safe and effective treatment for Stress Urinary Incontinence in women. The treatment is currently undergoing Phase I clinical study at the University Hospital of Zurich, where the first patient was treated in March 2020.

Stress Urinary Incontinence is a disease affecting more than 200 million people worldwide. It represents a condition with a prevalence of 20-50% in women, thereby creating a significant socio-economic burden. The currently available treatment strategies entail various complications and offer only short-term relief to the patients. According to the company, tissue engineering using autologous cells offers a feasible alternative for functional restoration of the damaged urinary sphincter muscle and represents an ideal treatment option that could reverse the underlying pathologic conditions.


Subscribe for alerts on new companies featured on Startups.Bio


May 24, 2022Aulos Bioscience
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
May 18, 2022Code Bio
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
May 9, 2022Muna Therapeutics
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that …
April 27, 2022Glyphic Biotechnologies
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
April 24, 2022ImmuneID 
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
April 15, 2022Flare Therapeutics
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …

Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.